SGLT2 inhibitors: control of glycemia and nephroprotection properties
Abstract
Recently were appeared a fundamentally new insulin-independent approach to the treatment of type 2 diabetes - reduce blood glucose levels by inhibiting proteins co-transporters SGLT2 (sodium glucose transporter) in the proximal tubules of the kidneys, which are responsible for the reabsorption of glucose. Inhibitors SGLT2 co-transporters is effective either as monotherapy or in combination with other antidiabetic drugs. Thus, according to the results of randomized controlled trials, therapy with this class of drugs was well tolerated. The incidence of hypoglycemia was not statistically different from the incidence of hypoglycemia in the placebo group. On the background of therapy was observed a stable decrease in body weight in patients with type 2 diabetes. Therapy with all drugs of a class of SGLT2 inhibitors was accompanied by a decrease in blood pressure and body weight. This class of drugs could potentially play an important role in the early stages of development of diabetic nephropathy, with potential nephrorotective effect, working on the level of reduction intraglomerular pressure of a single nephron. Insulin-independent mechanism of action and low risk of hypoglycaemia makes the SGLT2 inhibitors effective and safe addition to existing methods of control glycemia in patients with type 2 diabetes.
About the Authors
A. A. Volodin
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
M. L. Maximov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
V. G. Slobodyan
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Dedov II, Shestakova MV. The results of the implementation of the subprogram «diabetes» of the Federal target program «Prevention and struggle with socially significant diseases 2007–2012. Diabetes 2013; sp.issue: 2–48 (in Russian).
2. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773–795
3. Alyautdin RN, Zatsepilova TA, Romanov BK. Antianginal drugs. Russian medical jornal 2007; 4: 35–40 (in Russian).
4. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014; 37(suppl 1): 14–80.
5. Nauck M. Update on developments with SGLT-2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy 2014; 8: 1335–1380.
6. Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence, Diabetes Metab. 2014; 40 (6 Suppl 1): 4–11.
7. Storgaard H, Gluud LL, Christensen M, Knop FK, Vilsbøll The effects of sodium- glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials BMJ Open. 2014; 4(8): e005378.
8. DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, LaCreta FP, Griffen SC. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013; 36(10): 3169–3176.
9. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Rev 2005; 21: 31–8.
10. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510–15.
11. Brown GK. Glucose transporters: structure, function and consequences of deficiency J Inherit Metab Dis 2000 May; 23(3): 237–46.
12. Guyton AC, Hall JE. Textbook of Medical Physiology. 9th ed. Philadelphia, PA:W. B. Saunders Company; 1996: 315–330.
13. Silverman M, Turner RJ. Glucose transport in the renal proximal tubule. In:Windhager EE, ed. Handbook of Physiology Vol. II. New York, NY:Oxford University Press; 1992: 2017–2038).
14. Ganong WF. Renal function and micturition. In: Review of Medical Physiology. 21st ed. New York, NY: Lange Medical Books / McGraw Hill; 2003: 702–732.
15. Abdul-Ghani MA, DeFronzo RA Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008; 14: 782–790.
16. Kanwal A, Banerjee SK SGLT inhibitors: a novel target for diabetes Pharm Pat Anal. 2013 Jan; 2(1): 77–91.
17. Scheepers A, Joost HG, Schürmann A. The Glucose Transporter Families SGLT and GLUT: Molecular Basis of Normal and Aberrant Function. JPEN, J. Parenter. Enteral Nutr. 2004; 28: 364–371.
18. Wright, E. M. Renal Na(+)-Glucose Cotransporters. Am. J. Physiol. Renal Physiol. 2001; 280: 10–18.
19. Wallne, EI, Wada J, Tramonti G, Lin S Kanwar YS. Status of Glucose Transporters in the Mammalian Kidney and Renal Development. Ren. Fail. 2001; 23: 301–310.
20. YouG, LeeWS, Barros EJ, Kanai. Molecular Characteristics of Na(+) — Coupled Glucose Transporters in Adult and Embryonic Rat Kidney; J. Biol. Chem. 1995; 270: 29365–29371.
21. Hediger MA, Rhoads DB Molecular Physiology of Sodium-Glucose Cotransporters. Physiol. ReV. 1994; 74: 993–1026.
22. Dzhardins™ Label Information [Internet]. 2016 (cited 01 Dec 2016). Avaible from: http://www.grls.rosminzdrav.ru (in Russian).
23. Macha S, Brand T, Meinicke T, Link J, Broedl UC. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects Clin Ther. 2015; 6: 0149–2918(15)00850-4.
24. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT-2 inhibitor empagliflozin in patients with type 2 diabetes; Diabetes Obes Metab. 2013; 15(8): 721–8.
25. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ. EMPA-REG MET Trial Investigators Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo- controlled trial. Diabetes Care. 2014; 37(6): 1650–9.
26. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC. EMPA-REG METSU Trial Investigators Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double- blind, placebo-controlled trial; Diabetes Care. 2013; 36 (11): 3396–404.
27. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC. EMPAREGPIO™ trial investigators Empagliflozin improves glycaemic and weight control as addon therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial; Diabetes Obes Metab. 2014; 16(2): 147–58.
28. Maka S, Hedrington S, Davis N. The role of empagliflozin in the management of type 2 diabetes by patient profile. Therapeutics and Clinical Risk Management 2015; 5: 1–5.
29. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. EMPA-REG BASAL trial investigators Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double- blind, placebo- controlled trial; Diabetes Obes Metab. 2015; 6: 4.
30. Invokana™ Label Information [Internet]. 2016 (cited 01 Dec 2016). Avaible from: http:// www.grls.rosminzdrav.ru (in Russian).
31. Devineni D, Polidori D, Curtin CR, Murphy J, Wang SS, Stieltjes H, Wajs E Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Int J Clin Pharmacol Ther. 2015; 53(6): 438–46.
32. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4): 372–82.
33. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial; Diabetologia 2013; 56(12): 2582–92.
34. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, CanovatchelW, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type-2 diabetes inadequately controlled with metformin (CANTATA- SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 14(9896): 941–50.
35. Stenlöf K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study Curr Med Res Opin. 2014; 30(2): 163–75.
36. Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone; Diabetes Obes Metab. 2014; 16(5): 467–77.
37. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D. CANVAS Trial Collaborative Group. Efficacy and safety of canagliflozin, an inhibitor of sodium- glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015; 38(3): 03–11.
38. Ôîðñèãà™ Label Information [Internet]. 2016 (cited 01 Dec 2016). Avaible from: http://www.grls.rosminzdrav.ru (in Russian).
39. Maranghi M, Carnovale A, Durante C, Tarquini G, Tiseo G, Filetti S Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015; 11(1): 125–37.
40. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33(10): 2217–24
41. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012; 66(5): 446–56.
42. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF Effect of dapagliflozin in patients with type2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 26; 375(9733): 2223–33.
43. Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo- controlled trial. Diabetes Ther. 2014; 5(1): 267–83.
44. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT-2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35(7): 1473–8.
45. John PH, Wilding DM; Vincent W, Norman G, Andrea P. Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin: A Randomized Trial. Ann Intern Med. 2012; 156(6): 405–415.
46. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes N. Engl J Med. 2015; 373(22): 2117–28
47. Merkulov VA, Bunyatyan ND, Sakaeva IV, Lepakhin VK, Romanov BK, Yefremova TA. New legislative initiatives to improve drug safety in the European Union. The Bulletin of the Scientific center for expert evaluation of medical products 2013; 3: 45–48 (in Russian).
48. Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events Drug Saf. 2014; 37(10): 815–29.
49. Romanov BK. Calcium regulation of activity of lysosomal enzymes in myocardial. Dr. Med. Sci. [dissertation]. Ryazan; 2002 (in Russian).
50. Alyautdin RN, Romanov BK, Guseynov MD, Lopatin PV, Zilfikarov IN. Experimental screening evaluation of the stress-protection action of herbal remedies. Russian medical journal 2008; 3: 29–33 (in Russian).
51. Vaskova LB, Lopatin PV, Romanov BK. Pharmacoeconomics in pharmacy. Moscow: First Moscow state medical. University. I. M. Sechenov Of Ministry Of Healthcare Of Russia; 2012 (in Russian).
52. Romanov BK, Glagolev SV, Polivanov VA, Leonova MV. Monitoring of drug safety. Safety and risk of pharmacotherapy 2014; 4: 11–14 (in Russian).
53. Han HJ, Lee YJ, Park SH, Lee JH, Taub M. High glucose induced oxidative stress inhibits Na / glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Renal Physiol 2005; 288: 988–996.
54. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 1971; 28(1): 101–109.
55. Lee YJ, Han HJ. Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells. Kidney International 2007; 72: 27–35.
56. Thomson SC, Blantz RC. Glomerulotubular balance, tubuloglomerular feedback and salt homeostasis. J Am Soc Nephrol. 2008; 19(12): 2272–2275.
57. Nicola L. Sodium — Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes Am J Kidney Dis. 2014; 64(1): 16–24.
Review
For citations:
Volodin A.A., Maximov M.L., Slobodyan V.G., Alyautdin R.N. SGLT2 inhibitors: control of glycemia and nephroprotection properties. Safety and Risk of Pharmacotherapy. 2017;5(1):11-26. (In Russ.)
Views:
2034
Email this article 